Table 1.
Baseline characteristics of patients according to IHC subgroup.
| LUMINAL (n=26) | HER2 (n=21) | TN (n=20) | p-value* | ||
|---|---|---|---|---|---|
| Age | <35 | 0 | 2 (9.524) | 7 (35.00) | <0.001 |
| >=35 | 26 (100.0) | 19 (90.48) | 13 (65.00) | ||
| Number of missing data | 0 | 0 | 0 | ||
| Menopausal status | Pre | 11 (47.83) | 10 (52.63) | 15 (75.00) | 0.1673 |
| Post | 12 (52.17) | 9 (47.37) | 5 (25.00) | ||
| Number of missing data | 3 | 2 | 0 | ||
| SBR grade | 1 | 1 (4.167) | 3 (15.00) | 0.4876 | |
| 2 | 8 (33.33) | 6 (30.00) | 3 (21.43) | ||
| 3 | 15 (62.50) | 11 (55.00) | 11 (78.57) | ||
| Number of missing data | 2 | 1 | 6 | ||
| HDC regimen | Endoxan/Melphalan | 15 (57.69) | 12 (57.14) | 8 (40.00) | 0.4886 |
| NEM | 0 | 0 | 1 (5.000) | ||
| Epirubicine-Endoxan | 11 (42.31) | 9 (42.86) | 11 (55.00) | ||
| Number of missing data | 0 | 0 | 0 | ||
| HDCtiming | After conventional therapy | 17 (65.38) | 14 (66.67) | 10 (50.00) | 0.4694 |
| Séquentiel front-line | 9 (34.62) | 7 (33.33) | 10 (50.00) | ||
| Number of missing data | 0 | 0 | 0 | ||
| Dermal tumor emboli | Yes | 14 (70.00) | 13 (72.22) | 11 (64.71) | 0.8854 |
| No | 6 (30.00) | 5 (27.78) | 6 (35.29) | ||
| Number of missing data | 6 | 3 | 3 | ||
| pCR | Yes | 3 (15.79) | 9 (47.37) | 5 (27.78) | 0.1021 |
| No | 16 (84.21) | 10 (52.63) | 13 (72.22) | ||
| Number of missing data | 7 | 2 | 2 | ||
| Histological subtype | Ductal | 22 (88.00) | 18 (90.00) | 16 (88.89) | 0.9999 |
| Other | 3 (12.00) | 2 (10.00) | 2 (11.11) | ||
| Number of missing data | 1 | 1 | 2 | ||
| N Stage | N0 | 8 (32.00) | 11 (55.00) | 5 (31.25) | 0.5109 |
| N1 | 15 (60.00) | 8 (40.00) | 9 (56.25) | ||
| N2 | 2 (8.000) | 1 (5.000) | 2 (12.50) | ||
| Number of missing data | 1 | 1 | 4 |
IHC: Immuno histo chemical / TN: Triple Negative / HER2: Overexpression of human epidermal growth factor receptor 2 / NEM: Endoxan + Melphalan + Mitoxantrone /HDC: High dose Chemotherapy / pCR Pathological complete response.
*Chi-square or Fisher's exact test according to expected scores (see Patient and Methods part).